WALTHAM, Mass., Nov. 1 /PRNewswire/ -- Proteon Therapeutics (http://www.proteontherapeutics.com), a privately held biopharmaceutical company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases, is presenting tomorrow at the Annual Meeting of the American Society of Nephrology an abstract entitled "Recombinant Human Elastase (PRT-201) Dilates Outflow Veins in a Preclinical Model of Arteriovenous Fistula." Findings to be presented represent an important preclinical demonstration of the potential of PRT-201 to enhance arteriovenous fistula (AVF) surgery outcomes in patients requiring chronic hemodialysis. It is well documented that between 30 and 50 percent of AVFs, the preferred form of vascular access, fail to mature to usable access sites for dialysis patients.
"Vascular access related complications are a major cause of suffering and hospitalization for dialysis patients," said Timothy P. Noyes, the Company's President and CEO. "We believe that PRT-201 could potentially facilitate the creation of more reliable dialysis access sites."
About Vascular Access in Hemodialysis
Patients with end stage kidney disease must undergo periodic external
blood filtering by hemodialysis machines in order to remove fluid and
metabolic byproducts from their blood. Vascular surgeons prepare patients
for hemodialysis by creating access sites in the body that can be connected
to hemodialysis machines. These high flow access sites are usually created
by connecting an artery to a vein, resulting in a "shunt" of blood from the
artery to the vein. There are three main types of chronic hemodialysis
access sites: Arteriovenous fistulas are created by connecting veins
directly to arteries, arteriovenous grafts are created by connecting veins
to arteries with a segment of artificial tubing, and catheters are placed
directly in large vein
|SOURCE Proteon Therapeutics|
Copyright©2007 PR Newswire.
All rights reserved